Esta ampliación de dostarlimab, de GSK, incluye los tumores MMRp/MSS, que representan aproximadamente el 75% de los casos de ...

La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar ...

It has been tough sledding for fans of dividend stocks lately, but the latest economic news could help to smooth out the ride. Long-term bond yields have tumbled as a result, which should be good news ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Shalby Advanced Technologies Inc., USA, a step down subsidiary of the Company has received U.S. Food and Drug Administration ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...